Roche v. Promega
This article was originally published in The Gray Sheet
Executive Summary
Hoffmann-LaRoche and Roche Molecular Systems face trial in San Francisco federal court on claims that their patents for Taq DNA polymerase were obtained through fraud. If the court rules against Roche, the firm "stands to lose control not only over its Taq patents but may lose its critical [polymerase chain reaction] patents as well," Promega says. In 1996, the court ruled that Cetus, the inventor of the Taq patent, made some material omissions in its application to the U.S. Patent Office ("The Gray Sheet" Aug. 19, 1996, I&W-7)
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.